Skip to main content
SpringerLink
Log in

Maribavir

1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. ViroPharma Incorporated. ViroPharma Licenses Rights from GlaxoSmithKline for Product Candidate for Cytomegalovirus (CMV) in Immunocompromised Patients. Media Release: 11 Aug 2003. Available from URL: http://www.viropharma.com

    Google Scholar 

  2. ViroPharma Incorporated. ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients. Media Release: 28 Sep 2006. Available from URL: http://www.viropharma.com

    Google Scholar 

  3. ViroPharma Incorporated. FDA Grants Fast Track Status for ViroPharma’s Maribavir for Prevention of Cytomegalovirus Infection. Media Release: 7 Feb 2006. Available from URL: http://www.viropharma.com

    Google Scholar 

  4. ViroPharma Incorporated. ViroPharma Receives Orphan Drug Designation for Maribavir for Cytomegalovirus Viremia and Disease Indication. Media Release: 7 Feb 2007. Available from URL: http://www.viropharma.com

    Google Scholar 

  5. ViroPharma Incorporated. ViroPharma Initiates Maribavir Phase 2 Program In Bone Marrow Transplant Patients. Media Release: 27 Jul 2004. Available from URL: http://www.viropharma.com

    Google Scholar 

  6. ViroPharma Incorporated. ViroPharma Completes Enrollment in Phase 2 Clinical Study of Maribavir in Bone Marrow Transplant Patients. Media Release: 28 Nov 2005. Available from URL: http://www.viropharma.com

    Google Scholar 

  7. ViroPharma Incorporated. ViroPharma Announces Positive Phase 2 Results Demonstrating That Maribavir Significantly Reduces CMV Reactivation. Media Release: 29 Mar 2006. Available from URL: http://www.viropharma.com

    Google Scholar 

  8. ViroPharma Incorporated. ViroPharma Announces Presentation Of Phase 1 Clinical Data For Maribavir. Media Release: 7 Mar 2005. Available from URL: http://www.viropharma.com

    Google Scholar 

  9. Koszalka GW, Chamberlain SD, Harvey RJ. Benzimidazoles for the treatment of human cytomegalovirus. Antiviral Research 30: 43, Apr 1996

    Google Scholar 

  10. ViroPharma Incorporated. ViroPharma Initiates Clinical Program with Maribavir for Prevention of Cytomegalovirus (CMV) Infection in Transplant Patients. Media Release: 5 Feb 2004. Available from URL: http://www.viropharma.com

    Google Scholar 

  11. Drew WL, Lalezari JP, Wang LH, et al. In vivo anti-CMV activity and safety of oral 1263W94 in HIV-infected subjects with asymptomatic CMV shedding. Antiviral Research 37: 70, Mar 1998

    Google Scholar 

  12. Bidanset DJ, Rybak RJ, Collins DJ, et al. The effect of benzimidazole nucleosides on human cytomegalovirus repli- cation in the SCID-hu retinal and thymus/liver tissue implant models. Antiviral Research 50: 59 (plus oral presentation), Apr 2001

    Google Scholar 

  13. Williams SL, Bidanset DJ, Hartline CB, et al. In vitro activities of benzimidazole ribonucleosides against members of the herpesvirus family. 14th International Conference on Antiviral Research Late Breaker: 11, 8 Apr 2001

    Google Scholar 

  14. Selleseth DW, Talarico CL, Lutz MW. Interactions of GW1263 with other antiviral agents in the inhibition of the HCMV. 37th Interscience Conference on Antimicrobial Agents and Chemo- therapy: 225, 28 Sep 1997

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maribavir. Drugs R D 8, 188–192 (2007). https://doi.org/10.2165/00126839-200708030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200708030-00006

Keywords

Search

Navigation